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FEDERAL BIOTECHNOLOGY 
POLICY: THE PERILS OF 
PROGRESS AND THE RISKS OF 
UNCERTAINTY 
Senator Al Gore* 
Americans have a schizophrenic view of science and technol-
ogy. Some of our greatest heroes have been technological pio-
neers-from the Wright brothers to Lindbergh to Chuck Yeager. 
Until recently, we expressed unmitigated adoration for the 
scientists and engineers who put man in space. Yet at the same 
time, many Americans are generally uneasy about the triumph 
of technology in their own lives. One does not have to be a 
Luddite to rail against computers every now and then. 
In deciding how to allocate precious public resources in an era 
of limits, legislators must take public perceptions of science very 
seriously. Unfortunately, the public can prove to be quite fickle 
in these matters. It is not easy to keep funding a scientific proj-
ect when the American people keep changing their minds about 
it. 
Nuclear power once had almost universal support as a safe, 
environmentally superior source of energy. It still has many sup-
porters-but the public perception of nuclear technology has 
changed dramatically over the past two decades. 
Minds can change quicker still, as the Challenger accident 
sadly demonstrated. For years, NASA was worshipped by Con-
gress, the press, and the American public. The Challenger trag-
edy transformed the image of the space program almost over-
night. Now NASA must confront an atmosphere of skepticism, 
mistrust, and intensive scrutiny. America still supports space ex-
ploration and research, and Congress will continue to fund 
it-but not without a host of difficult questions. 
America may never write a blank check like that again. The 
fate of science and technology in the next hundred years will 
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depend largely on the public perception of what scientists intend 
to do with it. The more scientists can do to establish a steady, 
forthright, and reasonable relationship with the public, the bet-
ter off all of us will be. With care and cooperation, the scientific 
community can help assure that Luddites will not rule the 
twenty-first century. 
No field illustrates the inevitable tensions, as well as the po-
tential for cooperation, better than molecular biology. In the 
century since Gregor Mendel's death, we have not only come to 
understand the intricacies of genetics, but we are on the verge of 
being able to use it to change the basic forms of life itself. 
Not since we learned to split the atom has man seen so power-
ful a technology with such tremendous implications. Biotechnol-
ogy presents us with the ability to change and reshape the world 
as we know it. We will be able to study human blueprints and 
correct their architectural flaws. Soon we may learn to develop 
new and better strains of crops and livestock; to create new mir-
acle drugs; to treat and cure human diseases that have long 
seemed incurable; to fight hazardous wastes safely and at rea-
sonable expense; and to diminish our dependence on chemical 
pesticides. The economic potential is virtually unlimited, and 
the medical applications may well be miraculous. 
In November 1982, I chaired hearings on the ethics of human 
genetic engineering.1 It became clear at those hearings that we 
are beginning to unlock the mystery of human life itself. 
To show how much our knowledge has advanced in this area, 
one witness compared it to a satellite photographing the earth. 
Our early knowledge of the human genome was likened to pho-
tographs of the continents. We could see the broad outlines, but 
we did not know the specifics of the terrain. As the technology 
developed we have been able to "zoom in" on those continents 
until we could see cities, then streets, then houses, and now 
mailboxes. Soon, we will even be able to tell whether the flag on 
the mailbox is up or down-whether a gene is turned on or off. 
The implications of this knowledge are enormous. We already 
know that many serious diseases-sickle cell anemia, Tay Sachs, 
Lesch Nyhan Syndrome, cancer-have genetic bases. Genetic ex-
plorers have found possible gene markers for Huntington's dis-
ease, Alzheimer's disease, cystic fibrosis, and manic depression. 
This can be hard work-one researcher said it was like searching 
l. Human Genetic Engineering Hearings Before the Subcomm. on Investigations 
and Oversight of the House Comm. on Science and Technology, 97th Cong., 2d Sess. 
(1982) [hereinafter Human Genetics Engineering Hearings]. 
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for a house in a city without knowing the street address. In some 
areas, progress may seem distant. But without gene therapy, the 
chance of curing a disease like cystic fibrosis is nil. 
I. THE PERILS OF PROGRESS 
For every use of biotechnology there is a potential misuse. For 
every benefit, there is a possible hazard. Our challenge is to 
know when we are about to go too far. Unless we are prepared to 
deal rationally with this newfound power, we will realize none of 
its real benefits and find ourselves saddled with all of its 
problems. The nuclear arms race demonstrates the hazards of a 
technology developed with neither foresight nor planning. If we 
had taken more time to comprehend the implications of nuclear 
technology when it was created, we might have developed a 
keener appreciation for those choices before us. We might even 
have found a way to avoid the dilemma we have created. 
The science of genetic engineering presents amazing possibili-
ties, but it also holds the potential for enormous hazards. As 
these amazing possibilities come within our grasp, we must also 
consider potentially serious adverse consequences. Some new 
crops and livestock we develop may have no natural enemies and 
will be genetically superior to their predecessors. Like kudzu, 
starlings, and gypsy moths, these new organisms could get out of 
control. So could new microorganisms being created to "eat" 
hazardous waste. As we discover the genetic bases for many dis-
eases, we are also beginning to understand the biological essence 
of what makes us human. We must struggle to use that knowl-
edge wisely. 
In the process of manipulating plant life for the better, we can 
so easily make things worse-perhaps through the catastrophic 
release of unknown pathogens into the environment. Just as we 
are learning to alter somatic disease cells, we are also figuring 
out how to manipulate gamete cells-giving us the power no-
body wanted, to tamper with the genetic makeup of a generation 
yet unborn. 
Genetic screening is another example. In the workplace, em-
ployers could use screening to protect employees from danger. 
But at what point does protection become discrimination? When 
does the employer's wish to avoid even the remote possibility of 
a personal injury lawsuit override concern for the employee's 
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well-being? In several hearings I chaired on this issue,2 I discov-
ered that some companies were already using this technology to 
screen employees, and many others had considered it. 
An even more difficult ethical question involves the use of ge-
netic engineering to intervene in the human genome. By geneti-
cally engineering gametic cells, we could keep defective, disease-
causing genetic traits from being passed on to future 
generations. 
As wonderful as it would be to wipe out certain diseases for-
ever, the same technology will give us the power to make dra-
matic changes in individuals that may not be so desirable. Al-
though no one objects to curing disease, the ability to custom-
order our children is something else again. 
We are beginning to understand how to manipulate the genes 
that determine our basic physical characteristics-height, hair 
color, and so on. We are learning more and more about human 
growth genes, and we have already been able to influence physi-
cal traits in animals, such as fruit flies and mice. It is not hard to 
imagine that someday we will have the ability to influence such 
traits in our children. 
Genetic makeup appears to determine our mental and psycho-
logical characteristics as well. Unlocking the mystery of these 
genes could enable us to cure a host of illnesses, from manic de-
pression to retardation. Yet from there it would only be a short 
step to trying to soup up our brains. 
Rapid development of genetic engineering could turn out to be 
a mixed blessing unless we also develop a means to cope with it. 
Researchers are on the verge of replicating Creation, and we 
have scarcely given thought to the design. 
II. THE GENE REVOLUTION: SHARING THE WEALTH 
Of course, there is also the possibility that biotechnology will 
work all too well. Its potential impact on the food supply, for 
example, is enormous. Few expect that by accident we will set 
loose some genetically defective "Andromeda Strain." Given our 
past record in dealing with agriculture, we are far more likely to 
drown ourselves in a sea of excess grain. The Green Revolution 
made America the world's breadbasket, but it has also brought 
2. Genetic Screening and the Handling of High-Risk Groups in the Workplace: 
Hearings Before the Subcomm. on Investigations and Oversight of the House Comm. on 
Science and Technology, 97th Cong., 1st Sess. (1981). 
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on an age of intractable overproduction. Unless we plan more 
carefully, the Gene Revolution could do the same-on an even 
grander scale. 
What is the price of progress? Will the "supercow" trample 
the small dairy farmer? Could the family farm be genetically al-
tered out of existence? Meanwhile, will biotechnology help to 
feed the starving millions-or will the Third World be left 
behind? 
The biggest threat is overproduction. These are hard times 
down on the farm-and if anything, the prospects are worse. We 
live in an age of excess capacity. From the standpoint of the 
small farmer, even the Green Revolution has been a mixed bless-
ing. Increased agricultural efficiency forced many family farms 
out of business, and left others hostage to the increasing volatil-
ity of glutted commodity markets. 
How can the small farmer possibly survive the Gene Revolu-
tion? The effect of genetic advances on production will dwarf 
the triumphs of the past two decades. Bovine growth hormones 
already can make cows produce up to forty percent more milk. 3 
Scientists are working on "supercows," "superpigs," even 
"supersized salmon." Other experiments have led to multiple 
births, more rapid growth, and higher resistance to disease. Un-
less we can somehow find a way to create very hungry 
Superhumans, each of these advances may produce nothing but 
glut. · 
In the next few years, our capacity to expand the food supply 
will grow at an unprecedented rate. The Gene Revolution will do 
for animal products what the Green Revolution did for crop 
yields. Much to the farmers' chagrin, it will have the same effect 
on food prices as well. Robert Kalter, an agricultural economist 
at Cornell University, predicts that "the unparalleled speed and 
magnitude of the expected productivity gains" will flood com-
modity markets.• As prices fall, he fears that the cost of main-
taining price supports will rise so rapidly that the government 
may have to abandon the program. 
For the average farmer, most of these new developments in 
biotechnology will be out of reach. A quarter of a million family-
sized farms in this country, already on the ropes, will be hard 
pressed to afford biotech's high start-up costs. After the ruinous 
3. Rogers, Copeland & Hager, Tinkering with Nature, NEWSWEEK, May 26, 1986, at 
54, 55. 
4. Gabor, Fresh From the Labs, A Farming Revolution, U.S. NEWS & WORLD REP., 
Nov. 25, 1985, at 74. 
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expansion of farm debt in the 1970's, banks may be more reluc-
tant to lend small farmers money for expensive new invest-
ments-and quicker to foreclose on them if anything goes wrong. 
Only the large farms will be able to afford a new technology 
which, if it works, could drive their smaller competitors out of 
business. Biotechnology will be a hollow victory for science and 
for society if only the big boys survive to divide the spoils. 
It does not have to be that way. With the right planning, bio-
technology could be the salvation of the family farm rather than 
the death of it. One way or another, biotechnology will become a 
cornerstone of our future prosperity. The challenge is to make 
sure it will help those who need it-from the wheat grower in 
west Tennessee to the starving peasant farmer in west Africa. 
We can turn this revolution into the common man's revenge 
by changing our approach to agricultural research. In our all-out 
rush to boost total production during the Green Revolution, we 
stopped worrying about producers. We almost forgot the small 
farmer, who needed cost-effective applied technology. The yield 
on a large farm in Iowa is forty times that of a subsistence farm 
in Nigeria not just because American farmers are more efficient, 
but also because the world has yet to develop agricultural tech-
niques that work on a small scale. Traditionally, ninety-five per-
cent of all agricultural research has been geared toward agribusi-
ness, to ever greater efficiencies of scale. 
Today we are paying for that policy of bigger is better-with 
bigger farm debts, a bigger price-support program, and big trou-
bles for all but the biggest farms. We cannot afford to make that 
mistake again. Biotechnology can and ought to be a Great 
Equalizer, making a miraculous yield possible on even a small 
plot of land. 
That should be an important goal of our research. Instead of 
rewarding agribusiness interests or distributing academic pork 
barrel, government grants should target the individual farmer. 
Perhaps we will never see another USDA study on how long 
Americans take to cook breakfast. We should worry instead 
about what Americans eat for breakfast and how the farmer can 
provide a cheap, tasty, and nutritious product. 
Unless we consciously steer progress toward the little guy, it 
will trickle down too late to do much good. A Biotechnology Ex-
tension Service, for example, could offer technological assistance 
in agricultural areas. Biotechnology will bloom and grow only if 
it is affordable and easy to understand. 
The government might also consider a Rural Development 
Bank to give small farmers low-interest loans on appropriate 
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biotechnology. Eventually, we could apply our success in the 
Third World, so the areas that need progress most do not just 
fall further behind. 
Here at home, we can use our technological research to target 
the individual consumer. One biotech company now produces 
healthy snacks, like carrots that are extra-sweet and popcorn 
that tastes buttery without adding butter. Instead of continually 
trying to change people's diets, we may someday be able to take 
the dietary risk out of high-risk foods. 
The Gene Revolution is still young and full of possibilities. It 
can bring on a brave new era-or just much more of the same 
old thing. We can sit back and watch the gap widen between 
rich and poor, North and South, agribusinessman and family 
farmer-or we can use this fabulous opportunity to leap ahead 
together. 
Ill. UNCERTAIN RISKS AND THE RISK OF UNCERTAINTY 
Biotechnology is about to pose some very direct challenges to 
our sociopolitical institutions. For the field to go forward, it will 
need the faith of the American people behind it. 
Despite its considerable promise, this new technology got off 
to a rocky start. The manipulation of recombinant DNA was un-
popular from the outset. When news leaked out in the mid-
1970's that certain laboratories wanted to experiment with ge-
netic manipulation of various bacteria, the idea met with consid-
erable controversy. Cambridge, Massachusetts, actually banned 
such experimentation within the city limits, for fear that some 
unforeseen bacterium might slip out and wreak havoc in 
Harvard Y ard. 11 At the same time, some members of Congress 
introduced legislation to restrict or even ban such research 
outright.6 
5. Cambridge Council Bids Harvard Delay Its Gene Research, N.Y. Times, July 8, 
1976, at 12, col. 6. 
6. In the Senate, Senator Edward Kennedy introduced a bill that would have created 
a permanent national commission to regulate and monitor all recombinant DNA research 
in the United States. See Recombinant DNA Regulation Act, 1977: Hearings on S. 1217 
Before the Subcomm. on Health and Scientific Research of the Senate Comm. on 
Human Resources, 95th Cong., 1st Sess. (1977). In the House, several bills intended to 
regulate DNA research were introduced. For the text of these bills, see Recombinant 
DNA Research Act of 1977: Hearings on H.R. 4759 and H.R. 4849; H.R. 3191, H.R. 3591, 
H.R. 3592, and H.R. 5020; H.R. 4232; and H. Res. 131, Before the Subcomm. on Health 
and the Environment of the House Comm. on Interstate and Foreign Commerce, 95th 
Cong., 1st Sess. (1977). For a discussion of the scientific community's reaction to these 
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Fortunately, the controversy had a sober and happy ending. 
The National Institutes of Health adopted guidelines that ac-
commodated the interests of both researchers and the public. 7 
Research was able to continue. · 
Yet government and society are being tested once again in this 
field, on several fronts. Our ability to deal with these new con-
troversies will set the tone for social and scientific cooperation in 
the years to come. 
Back in 1983, the Subcommittee on Investigations and Over-
sight concluded that the gravest danger associated with the re-
lease of genetically altered organisms was not necessarily the re-
lease itself, but our inability and failure to make risk 
assessments.8 Four years later, we still have not developed ade-
quate standards for risk assessment. As a result, important ex-
periments like the use of genetically engineered microbes to 
fight frost formation (ice-minus) have been stalled, even though 
their benefits seem to far outweigh their possible dangers. 
Our subcommittee did not call for a new biotechnology bill or 
agency, concluding instead that government should encourage 
this new science, not stand in its way. But we did see the need 
for an interagency committee to sort out the conflicts and gaps 
in agency jurisdiction, and to coordinate the federal effort in re-
search and regulation. Yet those conflicts have only multiplied. 
The constant uncertainty has hurt industry and regulators 
alike-and the picture is not likely to clear up any time soon. 
In 1983, we predicted that the biggest and most difficult hur-
dle for biotechnology would be to develop a broad public con-
sensus for the science. The debate is just getting started, and the 
public still knows next to nothing about biotechnology. Soon the 
industry and the scientific community must realize that public 
perceptions will set the agenda for biotech regulation, research 
funding, and consumer support. No matter how important fu-
ture applications could be, they will not happen unless the pub-
lic is convinced that the science is safe, sound, and worthwhile. 
In fact, the American public may be the most overlooked ele-
ment in our current risk assessments. The debate over deliberate 
release has centered on the potential risks involved, but ulti-
mately the public perception· of those risks will determine the 
bills, see Schmeck, Scientists Seek to lnff,uence Legislation on Gene Research, N.Y. 
Times, July 6, 1977, at 15, col. 1. 
7. See Goodbye to Guidelines, NATURE, Feb. 4, 1982, at 356. 
8. STAFF OF HOUSE SUBCOMM. ON INVESTIGATIONS AND OVERSIGHT, TRANSMITTED TO THE 
HOUSE COMM. ON SCIENCE AND TECHNOLOGY, 98TH CONG., 2D SESS., THE ENVIRONMENTAL 
IMPACTS OF GENETIC ENGINEERING (Comm. Print 1984). 
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future of the experiments. Look at the changing fortunes of 
Tylenol. Over the years, millions of Americans have taken Tyle-
nol Extra-Strength Capsules. More people have probably died 
from accidental overdose or allergic reactions to Tylenol than 
from tampered pills. Yet after two dramatic episodes of poison-
ing, Johnson & Johnson decided that it could no longer market 
the drug in capsule form. 
It is up to the industry whether biotechnology will go the way 
of Tylenol Extra-Strength Capsules. The most important lesson 
of recent events is to level with people, and not to play down the 
risks in the hope that they will never materialize. Sooner or 
later, an accident will happen-and it could devastate the indus-
try if the public is unprepared or feels betrayed. The Bhopal 
catastrophe shows what can happen when people do not under-
stand the risks involved in what they are doing. We must not let 
the same wishful thinking poison biotechnology. 
The ice-minus stalemate was an example of the industry's fail-
ure to recognize the importance of public perception. Advanced 
Genetic Sciences (AGS), the company that makes ice-minus, for-
got about the people of Monterey County, where the first test of 
the product was set to take place. When local residents learned 
of the company's plans, they got scared. The area depends on 
agriculture, and people there did not want any highfalutin' 
scientists coming in and jeopardizing their livelihood. The peo-
ple convinced the Monterey County Board of Supervisors to 
place a moratorium on the project.9 Had AGS taken the time to 
educate the public, the snafu might never have happened. 
IV. THE REGULATORY MUDDLE 
So biotechnologists must be patient with democracy. Mean- · 
while, all of us in government must work to speed the demo-
cratic process along. These issues are tremendously complicated, 
and they are bound to get more so. But that is no reason for 
government to sit on its hands and wonder what to do next. We 
need a way to sort out the regulatory mess, so that the world's 
largest biotech community will not have to spend all its time 
fighting the world's largest judicial system. 
9. Rhein, The EPA Locks Gene-Splicers in the Lab, Bus. WK., Apr. 7, 1986, at 42. To 
add to AGS's woes, the EPA revoked a test permit when it discovered that AGS had 
initiated tests of ice-minus bacteria on an open rooftop nine months before receiving 
EPA approval for tests outside the laboratory. The EPA also fined the company $20,000. 
Rogers, Copeland & Hager, supra note 3, at 55. 
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Right now, the only federal effort to clear up this muddle is 
the administration's proposed Biotechnology Science Coordinat-
ing Committee (BSCC). Although some kind of interagency 
committee is necessary, I do not believe an interagency "discus-
sion group" can do the job. The BSCC has no vested authority 
to resolve disputes or to come up with a common policy that 
eliminates confusion and overlap. 
We will need to do better than that in order to resolve the 
tough questions that lie ahead. Will our regulatory system be 
able to keep pace? What will happen, for example, when scien-
tists find a way to produce a drug genetically for less than it 
costs to produce it by conventional means? Should the FDA reg-
ulate it as a new drug? The USDA will face the same dilemma 
with genetically altered seeds-what constitutes a new crop? 
We need a group with the power to settle disputes that arise. 
If the administration continues to be unable to provide such a 
group, this is one area where I would consider introducing 
legislation. 
Perhaps more importantly, we need to get our regulatory act 
together because our ability to compete depends on it. Unneces-
sary delays in review and approval could fritter away our lead in 
biotechnology research and development. With a trade deficit of 
$170 billion in 1986, 10 the United States cannot afford to jeop-
ardize its long-term competitive strengths. 
A recent cartoon summed up the frustrations of our research 
community. The drawing portrayed scientists' first close look at 
a molecule: in small print, it says "Made in Japan." It often 
seems that American inventors do all the work while cut-rate 
foreign imitators reap the profits. We must not let that happen 
to biotechnology. As our manufacturing industries lose ground, 
sophisticated value-added sectors like biotechnology will become 
· critically important to the American economy. 
To preserve our vital technological ·edge, government must 
maintain a strong commitment to research ·and development. 
Scientists are understandably concerned about the level of basic 
research in a time of limited resources. Trying to save a little on 
research today could cost us a lot more tomorrow. Gramm-Rud-
man-Hollings or not, we simply cannot afford to eat our seed 
corn. In fact, the federal government should start expanding its 
research base if it hopes to regulate biotechnology effectively in 
the future. 
10. In 1986, the trade deficit amounted to $166.3 billion. Auerbach, U.S. Trade D", i-
cit Balloons, WASH. POST, Apr. 15, 1987, at Al, col. 1, A18, col. 4. · 
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In these competitive times, industry and government will have 
to cooperate as best they can. Ideally, agencies and biotech com-
panies will get together to set the research agenda. We may need 
some kind of research consortium to pool government and in-
dustry efforts. More cooperation will be required to make sure 
that biotechnology products reach the market quickly. At the 
same time, intellectual property and patent rights can be 
strengthened to protect researchers, and other impediments to 
international trade can be removed. Eventually, we can hope to 
develop international standards and guidelines for the biotech-
nology industry. 
V. THE ETHICS OF GENES 
The new technology is developing so rapidly that it is out-run-
ning the ability of our social, ethical, and legal institutions to 
deal with it. Biotechnology presents myriad new challenges that 
can no longer be ignored. 
The last thing we need is some new form of heavy-handed reg-
ulatory structure that would hinder the development of biotech-
nology. The government should help guide biotech, but it must 
not control it. We must be careful not to burden the biotech 
industry with an uncertain climate. 
Even so, the human applications of genetic engineering pose 
profoundly difficult issues. The November 1982 hearings on 
human genetic engineering11 convinced me that our society is 
woefully unprepared to grapple with the serious ethical choices 
the new technology will raise. Unless we are careful, we may well 
stumble across the hazy line between good and bad, desirable 
and undesirable, ethical and unethical. The challenge we face is 
to know where that line falls, and to keep from crossing it. 
Scientists and government officials cannot find that line on 
their own. Our society will need a collective effort to understand 
the technology and its dilemmas. We must create a new body of 
ethics-a body of "genethics"-to help us make the difficult 
choices that lie ahead. 
It is not enough simply to declare a new technology safe and 
hope that the public will go away. If there is public concern over 
safety, then government and the scientific community had better 
work together to address it. The stakes are too great and public 
support is too vital to ignore. What we need is a well-defined 
11. See Human Genetic Engineering Hearings, supra note 1. 
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process to satisfy public concerns so that scientists can get on 
with their work. 
Scientists cannot resolve these troubling questions by them-
selves. These issues touch the core of our existence. Whether or 
not one endorses such biological adventures, it is vital that we 
resolve their implicit moral dilemmas. 
In bioethics, at least, we have begun to lay the groundwork for 
extensive public debate. I proposed legislation in the last Con-
gress that has created a Biomedical Ethics Board to bring to-
gether scientists, public officials, and laymen.12 Through such a 
forum, science and society can resolve these issues to everyone's 
satisfaction. The Biomedical Ethics Board is designed to antici-
pate future challenges to our political institutions and our ethi-
cal beliefs. It will be able to advise Congress and other branches 
of government on sound guidelines and reasonable standards. 
Our society will keep pace with science as long as scientists 
take the time to calm our fears and hear our concerns. We are 
running out of time. The technology is developing rapidly, and 
we must start making decisions soon. In 1982, a witness testified 
at my hearings that human gene therapy experiments were a 
decade away.13 But it appears that the first such tests will be 
conducted any day now. 
We are in the midst of a biotech boom. Scientists at Cold 
Springs Harbor Laboratory in New York have just launched a 
program to teach genetic engineering to students in high school. 
Without a coherent set of scientific and ethical guidelines, 
events may simply overtake us. Our experience with nuclear 
technology shows that hindsight does very little good. 
Developing the necessary consensus will require the coopera-
tion of all participants in the debate. No group is more crucial to 
the success of this effort than the scientific community. Those of 
us in government rely tremendously upon scientists for the as-
sessments we need to make reasoned judgments and formulate 
rational strategies. Scientists also set an important example. As 
one member of French Anderson's gene team said recently, 
when asked about the race to use gene therapy in a human pa-
12. The Health Research Extension Act of 1985, Pub. L. No. 99-158, § 11, 99 Stat. 
820, 883-85 (codified at 42 U.S.C.A. § 275 (West Supp. 1987)). The members of the Bi-
omedical Ethics Board in the 100th Congress are Rep. Willis Gradison (R-Ohio), Chair-
man; Sen. Albert Gore, Jr. (D-Tenn.), Vice-Chairman; Representatives Thomas Bliley 
(R-Va.), Thomas Luken (D-Ohio), J. Roy Rowland (D-Ga.), Thomas Tauke (R-Iowa), 
and Henry Waxman (D-Calif.); and Senators Dale Bumpers (D-Ark.), David 
Durenberger (R-Minn.), Gordon Humphrey (R-N.H.), Edward Kennedy (D-Mass.), and 
Lowell Weicker (R-Conn.). 
13. See Human Genetic Engineering Hearings, supra note 1. 
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tient: "You're dealing with people. It's important not only to be 
first, but to be right." 
If biotechnology is to proceed in this country, our society must 
believe that it is right, and that its benefits outweigh its draw-
backs. That means we must approach the technology with care, 
and develop a consensus about its appropriate applications. 
We always assume that somehow science will work everything 
out for us and everything will come out all right in the end. But 
that will not happen by itself-not if we let the march of tech-
nology overwhelm us. We must make an effort to choose the 
good effects and reject the bad. 
We cannot predict the future, but we can create it. Science 
and technology have always been the engines of human progress. 
Together we can make sure that over the next hundred years 
they drive humanity forward-and in a direction we have 
chosen. 

